IP Library › Granted Patent US 12,746,405
Granted Patent B2
US 12,746,405 · App. 17/955,656 · Granted Sep 29, 2026

Reducing electrosensation whilst treating a subject using alternating electric fields

Inventor: Kristen W. Carlson (Concord, MA)
Assignee: Novocure GmbH
A61N1/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,746,405
App. No.
17/955,656
Filed
Sep 29, 2022
Granted
Sep 29, 2026
Kind
B2
Art Unit
3796
USPC
607/76
Abstract

When treating a subject using alternating electric fields (e.g., using TTFields to treat a tumor), some subjects experience an electrosensation effect when the alternating electric field switches direction. This application describes a variety of approaches for reducing or eliminating this electrosensation. More specifically, during the course of treatment using alternating electric fields, additional electrical signals that reduce the subject's sensation are applied during each of a plurality of time intervals, and these additional electrical signals interact with the relevant nerve cells to reduce the sensations.

Claims (31)

1 . A method of treating a target region of a subject's body with an alternating electric field, the method comprising:

applying an alternating electric field to the target region during a course of treatment, wherein the alternating electric field has a frequency between 50 kHz and 500 kHz; and

applying an electrical signal to the subject's body during each of a plurality of time intervals during the course of the treatment, wherein the electrical signal is configured to ameliorate a sensation experienced by the subject that is caused by the applying of the alternating electric field.

2 . The method of claim 1 , wherein the alternating electric field has field lines that run through the subject's body between a first electrode element and a second electrode element, and wherein the electrical signal travels through the subject's body in a direction that is substantially perpendicular to the field lines.

3 . The method of claim 1 , wherein the alternating electric field is applied by imposing an AC voltage between a first electrode element configured for positioning on or in the subject's body and a second electrode element configured for positioning on or in the subject's body, the first electrode element having a front face,

wherein the electrical signal is applied between a third electrode element configured for positioning on or in the subject's body and a fourth electrode element configured for positioning on or in the subject's body, wherein the third electrode element has a front face having a centroid, and wherein the fourth electrode element has a front face having a centroid, and

wherein a line between the centroid of the front face of the third electrode element and the centroid of the front face of the fourth electrode element is substantially parallel to the front face of the first electrode element.

4 . The method of claim 1 , wherein an orientation of the alternating electric field repeatedly alternates between at least two different directions during the course of treatment, wherein the electrical signal is applied to a plurality of different areas of the subject's body during the course of the treatment, and wherein the application of the electrical signal to the different areas of the subject's body is synchronized with the alternation between the at least two different directions.

5 . The method of claim 1 , wherein the electrical signal during each of the plurality of time intervals increases an action potential threshold of nerve fibers.

6 . The method of claim 1 , wherein the electrical signal during each of the plurality of time intervals blocks a propagation of an action potential of nerve fibers.

7 . An apparatus for treating a target region of a subject's body with an alternating electric field, the apparatus comprising:

an AC voltage generator having a first AC output that operates at a frequency between 50-500 kHz; and

a signal generator configured to generate a first electrical signal during each of a plurality of first times during a course of treatment, wherein the first electrical signal is configured to ameliorate a sensation experienced by the subject that is caused by applying a first alternating electric field to the subject's body.

8 . The apparatus of claim 7 , wherein the first electrical signal is configured to increase an action potential threshold of nerve fibers in the subject's body or to block propagation of an action potential of nerve fibers in the subject's body.

9 . The apparatus of claim 7 , further comprising:

a first electrode element configured for positioning on or in the subject's body and a second electrode element configured for positioning on or in the subject's body, wherein the first AC output is applied between the first electrode element and the second electrode element; and

a third electrode element configured for positioning on or in the subject's body and a fourth electrode element configured for positioning on or in the subject's body, wherein the first electrical signal is applied between the third electrode element and the fourth electrode element.

10 . The apparatus of claim 9 , wherein the third electrode element is adjacent to and distinct from the first electrode element, and wherein the fourth electrode element is adjacent to and distinct from the first electrode element.

11 . The apparatus of claim 9 , wherein the first electrode element and the second electrode element are capacitively-coupled electrode elements, and wherein the third electrode element and the fourth electrode element are conductive electrode elements.

12 . The apparatus of claim 9 , wherein the first electrode element and the second electrode element are capacitively-coupled electrode elements, and wherein the third electrode element and the fourth electrode element are conductive electrode elements made using a platinum-iridium alloy.

13 . The apparatus of claim 9 , wherein a single electrode element serves as both the first electrode element and the third electrode element.

14 . The apparatus of claim 7 , wherein the AC voltage generator has a second AC output that operates at a frequency between 50-500 kHz, and wherein the AC voltage generator is configured to repeatedly alternate between (a) activating the first AC output and (b) activating the second AC output, and

wherein the signal generator is further configured to generate a second electrical signal during each of a plurality of second times during the course of the treatment, wherein the second electrical signal is configured to ameliorate a sensation experienced by the subject that is caused by applying a second alternating electric field to the subject's body.

15 . The apparatus of claim 14 , further comprising:

a first electrode element configured for positioning on or in the subject's body and a second electrode element configured for positioning on or in the subject's body, wherein the first AC output is applied between the first electrode element and the second electrode element;

a third electrode element configured for positioning on or in the subject's body and a fourth electrode element configured for positioning on or in the subject's body, wherein the first electrical signal is applied between the third electrode element and the fourth electrode element;

a fifth electrode element configured for positioning on or in the subject's body and a sixth electrode element configured for positioning on or in the subject's body, wherein the second AC output is applied between the fifth electrode element and the sixth electrode element; and

a seventh electrode element configured for positioning on or in the subject's body and an eighth electrode element configured for positioning on or in the subject's body, wherein the second electrical signal is applied between the seventh electrode element and the eighth electrode element.

16 . The apparatus of claim 15 , wherein the third electrode element is adjacent to and distinct from the first electrode element, wherein the fourth electrode element is adjacent to and distinct from the first electrode element, wherein the seventh electrode element is adjacent to and distinct from the fifth electrode element, and wherein the eighth electrode element is adjacent to and distinct from the fifth electrode element.

17 . The apparatus of claim 15 , wherein the first electrode element, the second electrode element, the fifth electrode element, and the sixth electrode element are capacitively-coupled electrode elements, and wherein the third electrode element, the fourth electrode element, the seventh electrode element, and the eighth electrode element are conductive electrode elements.

18 . The apparatus of claim 15 , wherein a single electrode element serves as both the first electrode element and the third electrode element, and wherein another single electrode element serves as both the fifth electrode element and the seventh electrode element.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2022
From: CARLSON, KRISTEN W.
To: NOVOCURE GMBH
Reel/Frame 061514/0679 →
Continuity (2)
Provisional Application 63250675 · Sep 30, 2021
Related Publication 20230098801A1 · Mar 30, 2023
References Cited (127)
US 6868289B2 · Palti · 2005 [cited by applicant]
US 7016725B2 · Palti · 2006 [cited by applicant]
US 7089054B2 · Palti · 2006 [cited by applicant]
US 7136699B2 · Palti · 2006 [cited by applicant]
US 7333852B2 · Palti · 2008 [cited by applicant]
US 7467011B2 · Palti · 2008 [cited by applicant]
US 7519420B2 · Palti · 2009 [cited by applicant]
US 7565205B2 · Palti · 2009 [cited by applicant]
US 7565206B2 · Palti · 2009 [cited by applicant]
US 7599745B2 · Palti · 2009 [cited by applicant]
US 7599746B2 · Palti · 2009 [cited by applicant]
US 7706890B2 · Palti · 2010 [cited by applicant]
US 7715921B2 · Palti · 2010 [cited by applicant]
US 7805201B2 · Palti · 2010 [cited by applicant]
US 7890183B2 · Palti et al. · 2011 [cited by applicant]
US 7912540B2 · Palti · 2011 [cited by applicant]
US 7917227B2 · Palti · 2011 [cited by applicant]
US 8019414B2 · Palti · 2011 [cited by applicant]
US 8027738B2 · Palti · 2011 [cited by applicant]
US 8170684B2 · Palti · 2012 [cited by applicant]
US 8175698B2 · Palti et al. · 2012 [cited by applicant]
US 8229555B2 · Palti · 2012 [cited by applicant]
US RE43618E · Palti · 2012 [cited by applicant]
US 8244345B2 · Palti · 2012 [cited by applicant]
US 8406870B2 · Palti · 2013 [cited by applicant]
US 8447395B2 · Palti et al. · 2013 [cited by applicant]
US 8447396B2 · Palti et al. · 2013 [cited by applicant]
US 8465533B2 · Palti · 2013 [cited by applicant]
US 8706261B2 · Palti · 2014 [cited by applicant]
US 8715203B2 · Palti · 2014 [cited by applicant]
US 8718756B2 · Paiti · 2014 [cited by applicant]
US 8764675B2 · Palti · 2014 [cited by applicant]
US 9023090B2 · Palti · 2015 [cited by applicant]
US 9023091B2 · Palti · 2015 [cited by applicant]
US 9039674B2 · Palti et al. · 2015 [cited by applicant]
US 9056203B2 · Palti et al. · 2015 [cited by applicant]
US 9440068B2 · Palti et al. · 2016 [cited by applicant]
US 9655669B2 · Palti et al. · 2017 [cited by applicant]
US 9750934B2 · Palti et al. · 2017 [cited by applicant]
US 9910453B2 · Wasserman et al. · 2018 [cited by applicant]
US 10188851B2 · Wenger et al. · 2019 [cited by applicant]
US 10441776B2 · Kirson et al. · 2019 [cited by applicant]
US 10779875B2 · Palti et al. · 2020 [cited by applicant]
US 10967167B2 · Hagemann et al. · 2021 [cited by applicant]
US 11191956B2 · Giladi et al. · 2021 [cited by applicant]
US 20040176804A1 · Palti · 2004 [cited by applicant]
US 20050209642A1 · Palti · 2005 [cited by examiner]
US 20060167499A1 · Palti · 2006 [cited by applicant]
US 20060276858A1 · Palti · 2006 [cited by applicant]
US 20070225766A1 · Palti · 2007 [cited by applicant]
US 20070239213A1 · Palti · 2007 [cited by applicant]
US 20090076366A1 · Palti · 2009 [cited by applicant]
US 20110184486A1 · De Ridder · 2011 [cited by examiner]
US 20120029419A1 · Palti · 2012 [cited by applicant]
US 20120283726A1 · Palti · 2012 [cited by applicant]
US 20140330268A1 · Palti et al. · 2014 [cited by applicant]
US 20170120041A1 · Wenger et al. · 2017 [cited by applicant]
US 20170215939A1 · Palti et al. · 2017 [cited by applicant]
US 20170281934A1 · Giladi et al. · 2017 [cited by applicant]
US 20180001075A1 · Kirson et al. · 2018 [cited by applicant]
US 20180008708A1 · Giladi et al. · 2018 [cited by applicant]
US 20180050200A1 · Wasserman et al. · 2018 [cited by applicant]
US 20180160933A1 · Urman et al. · 2018 [cited by applicant]
US 20180202991A1 · Giladi et al. · 2018 [cited by applicant]
US 20180280687A1 · Carter et al. · 2018 [cited by applicant]
US 20190117956A1 · Wenger et al. · 2019 [cited by applicant]
US 20190117963A1 · Travers et al. · 2019 [cited by applicant]
US 20190224474A1 · Yang et al. · 2019 [cited by applicant]
US 20190308016A1 · Wenger et al. · 2019 [cited by applicant]
US 20200001069A1 · Kirson et al. · 2020 [cited by applicant]
US 20200009376A1 · Chang et al. · 2020 [cited by applicant]
US 20200009377A1 · Chang et al. · 2020 [cited by applicant]
US 20200016067A1 · Gotlib et al. · 2020 [cited by applicant]
US 20200023179A1 · Bomzon et al. · 2020 [cited by applicant]
US 20200061360A1 · Hagemann et al. · 2020 [cited by applicant]
US 20200061361A1 · Hagemann et al. · 2020 [cited by applicant]
US 20200069937A1 · Naveh · 2020 [cited by examiner]
US 20200078582A1 · Alon et al. · 2020 [cited by applicant]
US 20200108031A1 · Borst et al. · 2020 [cited by applicant]
US 20200114141A1 · Bomzon et al. · 2020 [cited by applicant]
US 20200114142A1 · Bomzon et al. · 2020 [cited by applicant]
US 20200121728A1 · Wardak et al. · 2020 [cited by applicant]
US 20200129761A1 · Bomzon et al. · 2020 [cited by applicant]
US 20200146586A1 · Naveh et al. · 2020 [cited by applicant]
US 20200155835A1 · Wasserman et al. · 2020 [cited by applicant]
US 20200171297A1 · Kirson et al. · 2020 [cited by applicant]
US 20200179512A1 · Giladi et al. · 2020 [cited by applicant]
US 20200219261A1 · Shamir et al. · 2020 [cited by applicant]
US 20200269037A1 · Hagemann et al. · 2020 [cited by applicant]
US 20200269041A1 · Zeevi et al. · 2020 [cited by applicant]
US 20200368525A1 · Maag et al. · 2020 [cited by applicant]
US 20210031031A1 · Wasserman et al. · 2021 [cited by applicant]
US 20210038584A1 · Voloshin-Sela · 2021 [cited by applicant]
US 20210060334A1 · Avraham et al. · 2021 [cited by applicant]
US 20210069503A1 · Tran et al. · 2021 [cited by applicant]
US 20210138233A1 · Deslauriers · 2021 [cited by applicant]
US 20210162228A1 · Urman et al. · 2021 [cited by applicant]
US 20210187277A1 · Wasserman et al. · 2021 [cited by applicant]
US 20210196348A1 · Wasserman · 2021 [cited by applicant]
US 20210199640A1 · Patel et al. · 2021 [cited by applicant]
US 20210203250A1 · Wasserman · 2021 [cited by applicant]
US 20210268247A1 · Story et al. · 2021 [cited by applicant]
US 20210299440A1 · Deslauriers et al. · 2021 [cited by applicant]
US 20210308446A1 · Alon et al. · 2021 [cited by applicant]
US 20210330950A1 · Hagemann et al. · 2021 [cited by applicant]
US 20210346694A1 · Wasserman et al. · 2021 [cited by applicant]
US 20210379362A1 · Smith et al. · 2021 [cited by applicant]
US 20210408383A1 · Kalra et al. · 2021 [cited by applicant]
US 20220088374A1 · Ackermann · 2022 [cited by examiner]
US 20220095997A1 · Wasserman · 2022 [cited by applicant]
US 20220096821A1 · Kirson et al. · 2022 [cited by applicant]
US 20220118249A1 · Bomzon et al. · 2022 [cited by applicant]
US 20220161028A1 · Giladi et al. · 2022 [cited by applicant]
US 20220193435A1 · Wasserman et al. · 2022 [cited by applicant]
US 20220267445A1 · Tran et al. · 2022 [cited by applicant]
US 20220280787A1 · Bomzon et al. · 2022 [cited by applicant]
US 20220288395A1 · Voloshin-Sela et al. · 2022 [cited by applicant]
US 20220313992A1 · Wasserman · 2022 [cited by applicant]
US 20220323753A1 · Voloshin-Sela et al. · 2022 [cited by applicant]
CN 202844368U · 2013 [cited by applicant]
CN 104415454A · 2015 [cited by applicant]
WO 2000056395A1 · 2000 [cited by applicant]
Eggers et al., “Combining direct current and kilohertz frequency alternating current to mitigate onset activity during electrical nerve block,” Journal of Neural Engineering, vol. 18, p. 046010, Mar. 2021. [cited by applicant]
Muzquiz et al., “A Reversible Low Frequency Alternating Current Nerve Conduction Block Applied to Mammalian Autonomic Nerves,” Sensors, vol. 21, p. 4521, Jul. 2021. [cited by applicant]
Roldan et al., “Measurement of block thersholds in kiloHertz frequency alternating current peripheral nerve block,” J. Neurosci. Methods, vol. 315, pp. 48-54, Mar. 2019. [cited by applicant]
Zupanic et al., “Increasing the repetition frequency of electric pulse delivery reduces unpleasant sensations that occur in electrochemotherapy,” Neoplasma, vol. 54, No. 3, pp. 246-250, Jan. 2007. [cited by applicant]
International Search Report and Written Opinion issued in application PCT/IB2022/059265 dated Dec. 21, 2022. [cited by applicant]